DASATINIB (DASH) Tablet

Name: DASATINIB (DASH) Tablet
Brand: variable
Availability: InStock

$360.00

Dasatinib DASH 20/50/70 MG Tablet represents a significant therapeutic advance in the management of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, offering targeted therapy that can improve outcomes and quality of life for patients facing these challenging diseases. With careful monitoring, patient education,

Sku:

N/A

Tag:

DASATINIB DASH

Description

Dasatinib DASH 20/50/70 MG Tablet is a groundbreaking medication in the realm of oncology, offering a potent treatment option for individuals battling chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). With its active ingredient dasatinib, this oral tablet represents a significant advancement in the management of these hematologic malignancies, providing renewed hope and improved outcomes for patients confronting these challenging diagnoses.

Key Features:

Targeted Therapy: Dasatinib is a potent inhibitor of multiple tyrosine kinases, including BCR-ABL, SRC family kinases, and c-KIT. By targeting these pathways, dasatinib effectively suppresses the proliferation and survival of leukemia cells bearing the BCR-ABL fusion protein, which drives the pathogenesis of CML and Ph+ ALL.
Treatment of CML and Ph+ ALL: Dasatinib DASH Tablet is indicated for the treatment of adult patients with newly diagnosed chronic phase (CP) CML, as well as for the treatment of patients with chronic, accelerated, or blast phase CML who are resistant or intolerant to prior therapy, including imatinib. It is also approved for the treatment of adults with Ph+ ALL who are resistant or intolerant to prior therapy.
Multiple Strengths: Available in tablet form with strengths of 20mg, 50mg, and 70mg, Dasatinib DASH Tablet allows for personalized dosing tailored to individual patient needs and treatment plans, facilitating optimized therapeutic outcomes.
Oral Administration: Dasatinib DASH Tablet is administered orally once daily, with or without food. Patients should adhere strictly to the prescribed dosing schedule and follow healthcare provider instructions meticulously.
Efficacy: Clinical trials have demonstrated the efficacy of dasatinib in achieving hematologic and cytogenetic responses in patients with CML and Ph+ ALL. It has shown superiority over comparator treatments, both as a first-line therapy and in patients with resistance or intolerance to prior therapy.
Side Effects: Common side effects of Dasatinib may include myelosuppression (neutropenia, thrombocytopenia), fluid retention, gastrointestinal disturbances (nausea, diarrhea), fatigue, and headache. Patients should be closely monitored for adverse reactions, and dose adjustments or supportive care measures may be necessary to manage side effects.
Patient Education: Patients should receive comprehensive counseling on proper medication administration, potential side effects, and the importance of adherence to treatment. They should also be educated on the need for regular monitoring and reporting of any concerning symptoms to their healthcare provider.
Consultation with Healthcare Provider: Treatment with Dasatinib DASH Tablet should be initiated and monitored by a qualified hematologist or oncologist experienced in the management of CML and Ph+ ALL. Close collaboration between the patient and healthcare provider is essential throughout the treatment journey.
Access and Affordability: Efforts should be made to ensure access to Dasatinib for eligible patients, including exploring financial assistance programs and insurance coverage options to mitigate the financial burden of treatment.

In conclusion, Dasatinib DASH 20/50/70 MG Tablet represents a significant therapeutic advance in the management of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia, offering targeted therapy that can improve outcomes and quality of life for patients facing these challenging diseases. With careful monitoring, patient education, and access to treatment, Dasatinib holds promise in reshaping the landscape of leukemia care and providing hope for those affected by these conditions.